مقایسهٔ روش‌ها

	شاخص عملکردی بریتیش کالج روماتولوژی برای اسپوندیلیت آنکیلوزان (BASFI)	شاخص فعالیت بیماری در اسپوندیلیت آنکیلوزان حمام (BASDAI)	امتیاز فعالیت بیماری ۲۸ مفصلی (DAS28)	شاخص فعالیت بیماری لوپوس اریتماتوی سیستمیک ۲۰۰۰ (SLEDAI-2K)
حوزه	روماتولوژی	روماتولوژی	روماتولوژی	روماتولوژی
خانواده	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
سال پیدایش	1994	1994	1995	2002
پدیدآور	Calin et al.	Garrett et al.	Prevoo et al.	Gladman et al.
نوع	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)	Clinician-rated	Clinician-rated
منبع بنیادین	Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
نام‌های دیگر	BASFI, BAS-FI	BASDAI, BAS-DAI	DAS28, DAS28-CRP, DAS28-ESR	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
مرتبط	4	4	3	3
خلاصه	The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.